Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV-associated chronic lung disease

Loading...
Thumbnail Image

Authors

Flygel, Trym Thune
Hameiri-Bowen, Dan
Simms, Victoria
Rowland-Jones, Sarah
Ferrand, Rashida Abbas
Bandason, Tsitsi
Yindom, Louis-Marie
Odland, Jon Oyvind
Cavanagh, Jorunn Pauline
Flaegstad, Trond

Journal Title

Journal ISSN

Volume Title

Publisher

Wiley

Abstract

OBJECTIVES : Chronic lung disease is a recognized complication in children with HIV. Acute respiratory exacerbations (ARE) are common among this group and cause significant morbidity. Exhaled nitric oxide (eNO) is a known marker of local airway inflammation. We investigated the association between eNO and ARE, biomarkers of systemic inflammation, and the effect of azithromycin on eNO levels. METHODS : Individuals aged 6–19 years with HIV-associated chronic lung disease in Harare, Zimbabwe, were enrolled in a placebo-controlled randomized trial investigating the effect of 48-week azithromycin treatment on lung function and ARE. eNO levels and biomarkers were measured at inclusion and after treatment in a consecutively enrolled subset of participants. Linear regression and generalized linear models were used to study associations between eNO and ARE, biomarkers, and the effect of azithromycin on eNO levels. RESULTS : In total, 172 participants were included in this sub-study, 86 from the placebo group and 86 from the azithromycin group. Participants experiencing at least one ARE during follow-up had significantly higher eNO levels at baseline than participants who did not (geometric mean ratio 1.13, 95% confidence interval [CI] 1.03–1.24, p = 0.015), adjusted for trial arm, age, sex and history of tuberculosis. Matrix metalloproteinase (MMP)-3, -7, and -10 were significantly associated with higher baseline eNO levels. At 48 weeks, azithromycin treatment did not affect eNO levels (geometric mean ratio 0.86, 95% CI 0.72–1.03, p = 0.103). CONCLUSION : Higher baseline eNO levels were a risk factor for ARE. eNO was associated with proinflammatory biomarkers previously found to contribute to the development of chronic lung disease. The potential use of eNO as a marker of inflammation and risk factor for ARE in HIV-associated chronic lung disease needs further investigation.

Description

SUPPORTING INFORMATION : FIGURE S1. Box plot of eNO at baseline and 48 weeks by trial group and overall. AZM, azithromycin; eNO, exhaled nitric oxide. TABLE S1. Baseline characteristics of participants by trial group. TABLE S2. Effect of azithromycin on levels of eNO after 48 weeks of treatment using a generalized linear model. eNO, exhaled nitric oxide.

Keywords

Africa, Biomarkers, Chronic lung disease, Human immunodeficiency virus (HIV), Inflammation, Acute respiratory exacerbations (ARE), Exhaled nitric oxide (eNO), SDG-03: Good health and well-being

Sustainable Development Goals

SDG-03:Good heatlh and well-being

Citation

Flygel, T.T., Hameiri-Bowen, D., Simms, V., et al. Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV-associated chronic lung disease. HIV Medicine 2024; 25(2): 223‐232. doi:10.1111/hiv.13565.